Intramuscular anti-D treatment for immune thrombocytopenia

doi:10.1111/bjh.19091

Comment

. 2023 Nov;203(4):e109.

doi: 10.1111/bjh.19091. Epub 2023 Sep 8.

Intramuscular anti-D treatment for immune thrombocytopenia

Emily Jane Woo¹, Megha Kaushal²

Affiliations

¹ US Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), Office of Biostatistics and Pharmacoepidemiology, Silver Spring, Maryland, USA.
² FDA/CBER/Office of Therapeutic Products, Office of Clinical Evaluation, Division of Clinical Evaluation Hematology, Benign Hematology Branch, Silver Spring, Maryland, USA.

PMID: 37681547
DOI: 10.1111/bjh.19091

Comment

Intramuscular anti-D treatment for immune thrombocytopenia

Emily Jane Woo et al. Br J Haematol. 2023 Nov.

. 2023 Nov;203(4):e109.

doi: 10.1111/bjh.19091. Epub 2023 Sep 8.

Authors

Emily Jane Woo¹, Megha Kaushal²

Affiliations

¹ US Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), Office of Biostatistics and Pharmacoepidemiology, Silver Spring, Maryland, USA.
² FDA/CBER/Office of Therapeutic Products, Office of Clinical Evaluation, Division of Clinical Evaluation Hematology, Benign Hematology Branch, Silver Spring, Maryland, USA.

PMID: 37681547
DOI: 10.1111/bjh.19091

No abstract available

PubMed Disclaimer

Comment in

Intramuscular anti-D treatment for immune thrombocytopenia-Response.
Bussel JB. Bussel JB. Br J Haematol. 2023 Nov;203(4):e108. doi: 10.1111/bjh.19065. Epub 2023 Aug 29. Br J Haematol. 2023. PMID: 37644644 No abstract available.

Comment on

Intramuscular Anti-D treatment for immune thrombocytopenia: A single centre experience.
Lakhwani S, López-Las Heras A, Rodríguez-García P, Iraheta S, Martín-Santos T, Rodríguez-Salazar MJ, Machado P, Hernández MT. Lakhwani S, et al. Br J Haematol. 2023 Feb;200(3):353-357. doi: 10.1111/bjh.18484. Epub 2022 Oct 5. Br J Haematol. 2023. PMID: 36198407 Free PMC article.
Why should intramuscular anti-D be different from intravenous anti-D?
Bussel JB. Bussel JB. Br J Haematol. 2023 Feb;200(3):275-276. doi: 10.1111/bjh.18524. Epub 2022 Nov 21. Br J Haematol. 2023. PMID: 36408739

References

REFERENCES

1. Lakhwani S, López-Las Heras A, Rodríguez-García P, Iraheta S, Martín-Santos T, Rodríguez-Salazar MJ, et al. Intramuscular anti-D treatment for immune thrombocytopenia: a single centre experience. Br J Haematol. 2023;200(3):353-357.
1. Bussel JB. Why should intramuscular anti-D be different from intravenous anti-D? Br J Haematol. 2023;200(3):275-276.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley

[1] Lakhwani S, López-Las Heras A, Rodríguez-García P, Iraheta S, Martín-Santos T, Rodríguez-Salazar MJ, et al. Intramuscular anti-D treatment for immune thrombocytopenia: a single centre experience. Br J Haematol. 2023;200(3):353-357.

[2] Lakhwani S, López-Las Heras A, Rodríguez-García P, Iraheta S, Martín-Santos T, Rodríguez-Salazar MJ, et al. Intramuscular anti-D treatment for immune thrombocytopenia: a single centre experience. Br J Haematol. 2023;200(3):353-357.

[3] Bussel JB. Why should intramuscular anti-D be different from intravenous anti-D? Br J Haematol. 2023;200(3):275-276.

[4] Bussel JB. Why should intramuscular anti-D be different from intravenous anti-D? Br J Haematol. 2023;200(3):275-276.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Intramuscular anti-D treatment for immune thrombocytopenia

Affiliations

Intramuscular anti-D treatment for immune thrombocytopenia

Authors

Affiliations

Comment in

Comment on

Similar articles

References

REFERENCES

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources